Latest Safety News

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Australian Strategic Materials (ASM) has made significant strides in its mine to metals strategy during the March 2025 quarter, including plans for US expansion and progress at its Dubbo Project and Korean Metals Plant. The company is positioning itself as a key alternative supply chain amid escalating geopolitical tensions and export restrictions.

New Murchison Gold Limited has confirmed ultra-high-grade gold mineralisation at unprecedented depths below its Crown Prince open pit project, signalling strong underground potential. The latest diamond drilling results include a staggering 0.28m at 17,240 g/t gold, reshaping the project's future development outlook.

Native Mineral Resources Holdings Limited (NMR) has made significant progress on its Charters Towers Gold Project, completing key plant refurbishments and securing $15.9 million in funding to support a planned gold production restart in Q3 2025.

MAC Copper Limited reported steady Q1 2025 copper production amid rising costs but strengthened its balance sheet through a significant debt refinancing, positioning itself for a 23% production increase by 2026.

Lotus Resources is on track to restart uranium production at its Kayelekera project in Malawi by Q3 2025, backed by strong funding and binding offtake agreements covering up to 3.8 million pounds of uranium from 2026. Meanwhile, its Letlhakane project in Botswana advances with an updated scoping study supporting robust production potential.

Coronado Global Resources delivered March quarter production in line with plans despite Queensland rainfall, progressing key expansion projects and implementing significant cost reductions to navigate challenging metallurgical coal markets.

RocketDNA has become the first drone operator to earn simultaneous BARS Gold Certification in Australia and Africa, while progressing a key pilot project with Rio Tinto despite a 19% revenue decline in Q1 2025.

Island Pharmaceuticals has completed dosing in the Phase 2b cohort of its dengue fever trial, with pharmacokinetic targets met and top-line results expected next month. The company also strengthened its balance sheet by raising $1.94 million through option exercises.

Santos Limited’s 2024 Annual Report reveals a 5% drop in production and a 9% decline in sales revenue, yet highlights significant progress in carbon capture and storage and emissions reduction targets.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

St Barbara Limited reports a strong quarter with Simberi gold production up 37% and a robust US$235 million expansion plan, while navigating a critical tax assessment review in Papua New Guinea.